When every hour counts
the new therapeutic approach for
multi-organ failure in
the intensive care unit.
When Every Hour Counts
Multi-organ failure is one of the greatest challenges in intensive care medicine. When the liver, kidneys or lungs begin to fail, it often becomes a race against time.
Despite advances in modern medicine, many patients still die from the consequences of these life-threatening conditions.
This is precisely where ADVOS multi therapy comes in.
Nominated for Germany’s most prestigious innovation Award
The Deutscher Zukunftspreis celebrates innovations that make a real difference to society.
The nomination of ADVOS multi therapy reflects over twenty years of dedication, scientific excellence, and collaboration across medicine, research, and industry.
Now, we eagerly await the final decision.
The award ceremony will be held on 18 November 2026 in Berlin.
Until then, fingers crossed.
One idea that changed intensive care medicine
2004
Liver support therapy using regenerated albumin (albumin dialysis)
Foundation of Hepa Wash GmbH
2008
In-vivo: reduction of mortality in acute liver failure; improvement of major organ functions
2011
Prototype & dialysis fluids for the clinical pilot study
Certified ISO 13485
2013
EU market approval (CE mark, MDD 93/42)
2014
Use of the therapy in 1st hospital
2016
2018
2019
2021
2025
Next Generation ADVOS System
The people behind the innovation
Dr Ing. Claus Jessen
Chief Executive Officer
“We break the vicious cycle
of multi-organ failure.
Our therapy supports the
entire organism,
not just individual organs.”
Priv.-Doz. Tobias Bingold, MD
Chief Medical Officer
“Ultimately, our goal is to
give patients
the time their bodies need
to recover and heal
themselves.”
Christoph Hüßtege, MSc
Head of Research & Development
“What drives me is
understanding complex challenges
and turning them into
meaningful solutions.”
How the technology works
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
ADVOS multi therapy is already being used in clinical practice today.
11.500+
Treatments performed
60
Devices in use
30
Intensivse care units in Germany and Austria
None of this would have been possible without:
The ADVITOS-Team
Our clinical collaboration partners
Photos for media representatives
Dr Claus Jessen, PD Dr Tobias Bingold and Christoph Hüßtege, MSc in the production facility
From Vision to ADVOS multi therapy
Meet ADVITOS
This film, produced as part of the Global Health Initiative, introduces ADVITOS and our innovative ADVOS multi Therapy.
The ADVOS multi therapy in Scientific Publications
Scientific evidence is at the heart of medical innovation.
We have compiled a selection of national and international publications and conference posters highlighting the clinical application, scientific evaluation and ongoing development of the ADVOS multi therapy.
Press Contact
Would you like to learn more about the nomination of the ADVOS multi therapy?
We would be pleased to hear from you:
Martina Petkov
Head of Business Development
martina.petkov@advitos.com